Cancer and New Drugs · global
New Evidence in Advanced Breast Cancer Treatment: Iza-bren Achieves 8.2 Months of Progression-Free Survival in Phase 3 Trial
In patients previously treated with endocrine therapy, CDK4/6 inhibitors, and chemotherapy, this dual-target antibody-drug conjugate delayed disease progression. However, a higher rate of severe side effects and immature overall survival data also limit how the efficacy findings can be interpreted.
When advanced breast cancer develops resistance to successive treatments, how long the next drug can keep the disease stable becomes a particularly pressing question. Bristol Myers Squibb (BMS) and SystImmune announced on October 23 that the investigational drug izalontamab brengitecan (iza-bren for short) extended median progression-free survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer from 4.0 months with chemotherapy to 8.2 months in the Phase 3 PANKU-Breast01 study.
The randomized trial, conducted in China, enrolled 383 participants: 190 in the iza-bren group and 193 in the chemotherapy group. All participants had received endocrine therapy, CDK4/6 inhibitors, and taxanes, as well as one or two lines of chemotherapy for advanced disease. In the control group, physicians selected eribulin, capecitabine, gemcitabine, or vinorelbine. SystImmune's pre-conference announcement confirmed that the study is also known as BL-B01D1-306 and that its results were included among the late-breaking abstracts at this year's European Society for Medical Oncology (ESMO) Congress.
According to blinded independent central review, at a median follow-up of 15.2 months for progression-free survival, the hazard ratio for disease progression or death in the iza-bren group was 0.41, equivalent to a 59% relative risk reduction (95% confidence interval, 0.33 to 0.53; P<0.0001). This endpoint measures the time during which the disease has not progressed and the patient remains alive; it cannot be directly interpreted as a doubling of life expectancy. Overall survival data from the trial remain immature, so it is not yet possible to confirm whether patients live longer as a result.
Iza-bren is a bispecific antibody-drug conjugate (ADC) that recognizes both EGFR and HER3. It is designed so that the antibody binds to targets on the surface of cancer cells and, after cellular uptake, releases a topoisomerase I inhibitor that disrupts the cells' ability to process DNA, thereby killing cancer cells. These results support the clinical potential of this dual-target design, but the trial compared it with chemotherapy and therefore cannot establish that it is superior to other ADCs.
Alongside efficacy, the burden of side effects also needs to be weighed. Conference data compiled by OncoDaily showed that grade 3 or higher treatment-related adverse events occurred in 85.3% of the iza-bren group and 65.8% of the chemotherapy group; 64.7% of the iza-bren group required dose reductions. The company announcement stated that the more severe adverse events primarily involved the blood system, and that 1.6% permanently discontinued treatment because of treatment-related adverse events. Two participants also developed adjudicated interstitial lung disease, which was grade 1 or grade 2. A low discontinuation rate does not mean that close monitoring and dose adjustments are unnecessary during treatment.
For patients whose disease continues to progress after multiple treatments, this study provides new evidence of longer disease control. However, the results come from a specific population treated in China. Their applicability to other regions and how to sequence iza-bren with other ADCs remain subjects for further research. Iza-bren remained an investigational drug at the time of this announcement. Further overall survival follow-up and a more complete benefit-risk assessment will determine how this additional period of disease control can translate into a clinical treatment option.